DaVita Inc. (DVA) Stock Price & How to Invest

DaVita Inc. (NYSE: DVA) is a Denver, Colorado based kidney care company and the largest provider of dialysis services in the United States. As of June 30, 2026 it treated approximately 298,500 patients across 3,266 outpatient dialysis centers, of which 2,671 are in the US and 595 are spread across 14 other countries. The core business is straightforward and repetitive: patients with end stage renal disease come in roughly three times a week for a treatment that keeps them alive, and DaVita bills a payer for each treatment. Around that base the company runs two smaller segments, an international dialysis business and Integrated Kidney Care (IKC), a value-based care arm that took risk on roughly 62,600 patients and about $5.4 billion of annualized medical spend as of early 2026.

The investment picture is unusual for healthcare. Treatment volumes barely grow, up roughly 0.5% to 0.75% year over year on management's own 2026 target, and total revenue grows in the mid single digits. What has driven the stock historically is capital allocation: DaVita pays no dividend and instead converts nearly all free cash flow into share repurchases, retiring a large fraction of its own float over the past decade, which turns flat operating income into double-digit earnings per share growth. Berkshire Hathaway is the dominant shareholder at roughly 45% of shares outstanding, under an agreement that obliges DaVita to buy back stock whenever Berkshire's stake crosses that threshold. The economics underneath are lopsided: government programs cover the large majority of patients at rates near or below cost, and a thin slice of commercially insured patients generates most of the profit, which is why the expiration of enhanced Affordable Care Act premium subsidies and the resulting drift of patients toward government coverage is the single most consequential variable for the next two years.

Payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027. Revenue per treatment fell about $2 sequentially in Q2 2026 on that mix shift plus lower phosphate binder revenue, and management guided to slightly negative revenue per treatment growth in the second half, while patient care costs per treatment stayed elevated. Leverage sits around 3.37 times consolidated EBITDA, at the upper end of the stated 3.0 to 3.5 times target, so the buyback, the debt load and the earnings base are tightly coupled and a payer-mix shock compresses all three at once. Berkshire Hathaway's roughly 45% position is both an anchor and an overhang, since the repurchase agreement means a meaningful slice of company cash is committed to buying one holder's shares rather than allocated freely. Longer term, wider GLP-1 use slowing chronic kidney disease progression, transplant advances, government reimbursement rate decisions, labor cost inflation at the clinic level, and cybersecurity exposure after the April 2025 ransomware incident all sit on the risk register.

7 analysts publish price targets on DVA, averaging $208.57 against a $188.69 price as of August 2026, or +10.5%. The published targets run from $145.00 to $270.00, a moderate spread, and the ratings split 2 buy, 4 hold, 2 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DVA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on DaVita Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The buyback is the growth engine. DaVita pays no dividend and directs essentially all free cash flow into repurchases. The most optimistic published target, $270.00, assumes this works close to its best case.

The case against. Payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027. The most pessimistic target, $145.00, is roughly what DVA is worth if this bites instead.

Read the full bull and bear case on DVA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see DaVita Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$14.0 billion (up ~6.4% year over year)
• Revenue (Q2 2026): ~$3.55 billion, with adjusted operating income of ~$579 million
• Net Income (TTM): ~$847 million, with trailing EPS of ~$12.11
• FY 2026 Adjusted EPS Guidance: ~$14.10 to ~$15.20 (midpoint ~$14.65), reaffirmed not raised
• Market Cap / P/E: ~$12 billion, ~16x trailing and ~12x forward earnings
• Leverage / Dividend: ~3.37x consolidated EBITDA (target 3.0x to 3.5x); no dividend, all cash return via buybacks

DVA trades at a visible discount to the broader healthcare sector, roughly 16x trailing and 12x forward earnings versus a healthcare industry average in the mid 20s, and that gap is the argument in both directions. Bulls read it as a cheap, defensive, non-discretionary cash machine with a shrinking share count. Bears read it as an appropriate multiple for a business with sub-1% volume growth, negative revenue-per-treatment guidance for the second half of 2026, roughly 3.4x leverage, and a profit pool concentrated in a thin commercially insured minority of patients that is actively eroding. The stock fell sharply in early August 2026 after Q2 results beat on both revenue and adjusted EPS but management reaffirmed rather than raised full-year guidance at a midpoint below consensus, which is a reminder that the multiple is doing very little cushioning work when the mix narrative turns.

Other names that sit close to DVA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get DVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so DVA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

DaVita is a cash-generative dialysis duopolist trading around ~16x trailing earnings and ~12x forward earnings as of August 2026, where the buyback does the compounding and a shrinking commercially insured patient mix is the thing that can undo it.

Whether DVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DVA a buy or a sell?, and where the stock could go from here in the DVA stock forecast.

For income investors, whether DVA pays a dividend and how the payout looks is covered in does DVA pay a dividend? And to weigh DVA against a peer, read the full side-by-side comparisons: DVA vs HNGE and DVA vs BMY.